Ambulatory blood pressure monitoring (ABPM) is a crucial tool for diagnosing primary and secondary hypertension, predicting cardiovascular disease and mortality, and identifying white-coat and masked subtypes. It provides a 24-hour account of a patient's state, with a diagnostic threshold of ≥130/80 mmHg over 24 hours. ABPM offers better prognosis of hypertension-mediated organ damage, is more sensitive to CV outcomes, and can provide stronger prognostic evidence.

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals

Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.